Advertisement
Advertisement
U.S. Markets close in 14 mins
Advertisement
Advertisement
Advertisement
Advertisement

Inventiva S.A. (IVA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
12.00+0.10 (+0.84%)
As of 03:03PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close11.90
Open12.11
Bid12.00 x 1100
Ask12.05 x 1300
Day's Range12.00 - 12.11
52 Week Range10.52 - 17.90
Volume1,221
Avg. Volume4,351
Market Cap488.912M
Beta (5Y Monthly)0.90
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Inventiva announces participation at several conferences in January and February 2022

    Daix (France), Long Island City (New York, United States), January 20, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that the Company’s leadership will participate in two upcoming conferences in January and February 2022. The event

  • GlobeNewswire

    Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

    Daix (France), Long Island City (New York), January 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux. Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resourc

  • GlobeNewswire

    Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference

    Daix (France), Long Island City (New York), December 16, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate overview, followed by a Q&A

Advertisement
Advertisement